| Literature DB >> 35906380 |
Masashi Kubota1, Toshinari Yamasaki2, Shiori Murata2, Yohei Abe2, Yoichiro Tohi2, Yuta Mine2, Hiroki Hagimoto2, Hidetoshi Kokubun2, Issei Suzuki2, Naofumi Tsutsumi2, Koji Inoue2, Mutsushi Kawakita2.
Abstract
To evaluate the surgical and functional outcomes between robot-assisted (CRO-RAPN) vs. laparoscopic (CRO-LPN) methods of cortical-renorrhaphy-omitting partial nephrectomy. Between July 2012 and June 2020, patients with localized clinical T1-2 renal masses who underwent CRO-RAPN or CRO-LPN were reviewed. The outcomes of the two groups were compared using propensity-score matching. Trifecta was defined as negative surgical margin, warm ischemic time < 25 min, and absence of complications of Clavien-Dindo grade III or more until three months postoperatively. The preservation rate of the estimated glomerular filtration rate (eGFR) was evaluated at six months postoperatively. Among 291 patients (CRO-RAPN, n = 210; CRO-LPN, n = 81) included in the study, 150 matched pairs of patients were analyzed. Compared to the CRO-LPN group, the CRO-RAPN group was associated with shorter warm ischemic time (13 min vs. 20 min, P < 0.001), shorter total operation time (162 min vs. 212 min, P < 0.001), less estimated blood loss (40 mL vs. 119 mL, P = 0.002), lower incidence of overall complications (3% vs. 16%, P = 0.001), higher preservation rate of eGFR at six months postoperatively (93% vs. 89%, P = 0.003), and higher trifecta achievement rate (84% vs. 64%, P = 0.004). CRO-RAPN contributed to shorter warm ischemic time, less blood loss, fewer complications, and higher preservation of renal function, all of which allowed this technique to achieve a higher rate of trifecta compared to CRO-LPN.Entities:
Mesh:
Year: 2022 PMID: 35906380 PMCID: PMC9338244 DOI: 10.1038/s41598-022-17496-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1The cortical-renorrhaphy-omitting surgical procedure during partial nephrectomy in this study. In cases without intervention of the renal sinus or urinary tract, the inner suture was omitted and the operation was completed without suturing (a, c). If the renal sinus or urinary tract was opened, an inner suture was performed (b). (a) Tumor resection technique: the renal parenchyma was bluntly dissected along with fiber lines. Bleeding from the cortical or parenchymal vasculature was controlled by soft coagulation. (b) Inner suture technique: opened renal sinuses or urinary collecting systems were closed by running a suture in the parenchymal layer with shallow stitch by 3–0 V-LOC 180 V20 (Covidien; New Haven, CT, USA). (c) Renal cortical hemostasis: cortical renorrhaphy was omitted, and the sheet-type absorbable hemostats (TachoSil; CSL Behring) were onlayed on the tumor bed.
Figure 2Flow diagram of patient enrolment.
Patient characteristics of the CRO-RAPN and CRO-LPN groups before and after propensity-score matching.
| Parameters | Before propensity-score matching | After propensity-score matching | ||||
|---|---|---|---|---|---|---|
| CRO-RAPNf group | CRO-LPNg group | CRO-RAPN group | CRO-LPN group | |||
| Number of patients | 210 | 81 | 75 | 75 | ||
| Median age, years (IQRa) | 67 (57–75) | 68 (54–76) | 0.79 | 67 (57–74) | 68 (52–75) | 0.77 |
| Male sex, n (%) | 128 (61) | 50 (62) | 0.51 | 49 (65) | 46 (61) | 0.37 |
| Median BMIb, kg/m2 (IQR) | 23.9 (21.5–26.4) | 24.3 (21.8–25.9) | 0.96 | 23.6 (20.5–26.2) | 24.3 (22.0–26.0) | 0.39 |
| ASA PSc 3 or more, n (%) | 25 (12) | 8 (10) | 0.40 | 11 (15) | 7 (9) | 0.23 |
| eGFRd, mL/min/1.73m2 (IQR) | 67 (55–77) | 73 (56–85) | 0.040 | 68 (59–81) | 73 (56–85) | 0.31 |
| Grade 1 or 2 (60 mL/min/1.73 m2, or more) | 143 (68) | 60 (74) | 0.55 | 56 (74) | 56 (74) | 1.0 |
| Grade 3a or 3b (30–59 mL/min/1.73 m2) | 58 (28) | 19 (23) | 17 (23) | 17 (23) | ||
| Grade 4 or 5 (29 mL/min/1.73 m2, or less) | 9 (4) | 2 (2) | 2 (3) | 2 (3) | ||
| Right side tumor, n (%) | 97 (46) | 41 (51) | 0.29 | 42 (56) | 36 (48) | 0.21 |
| Tumor size, mm (IQR) | 30 (22–39) | 29 (23–37) | 0.84 | 25 (18–39) | 29 (23–37) | 0.21 |
| T1a | 159 (75) | 64 (79) | 0.59 | 58 (77) | 60 (80) | 0.81 |
| T1b | 44 (22) | 16 (20) | 15 (20) | 14 (19) | ||
| T2 | 7 (3) | 1 (1) | 2 (3) | 1 (1) | ||
| 4–6 (Low) | 95 (45) | 48 (59) | 0.047 | 47 (63) | 44 (59) | 0.68 |
| 7–9 (Intermediate) | 89 (42) | 29 (36) | 26 (35) | 27 (36) | ||
| 10–12 (High) | 26 (13) | 4 (5) | 2 (3) | 4 (5) | ||
| Off-clamp procedure, n (%) | 13 (6) | 19 (23) | < 0.001 | 12 (16) | 13 (17) | 0.50 |
ainterquartile range; bbody mass index; cAmerican Society of Anesthesiologists Physical Status classification; destimated glomerular filtration rate; echronic kidney disease; fcortical-renorrhaphy-omitting robot-assisted partial nephrectomy; gcortical-renorrhaphy-omitting laparoscopic partial nephrectomy.
Surgical outcomes and complications of the CRO-RAPN and CRO-LPN groups before and after propensity-score matching.
| Parameters | Before propensity-score matching | After propensity-score matching | ||||
|---|---|---|---|---|---|---|
| CRO-RAPNc group | CRO-LPNd group | CRO-RAPN group | CRO-LPN group | |||
| Number of patients | 210 | 81 | 75 | 75 | ||
| Median total operation time, minutes (IQRa) | 169 (144–196) | 212 (183–238) | < 0.001 | 162 (139–181) | 212 (184–237) | < 0.001 |
| Median warm ischemic time, minutes (IQR) | 16 (11–23) | 20 (16–28) | < 0.001 | 13 (10–21) | 20 (16–28) | < 0.001 |
| Median blood loss, mL (IQR) | 40 (15–90) | 119 (40–300) | < 0.001 | 40 (10–90) | 119 (40–300) | 0.002 |
| Transfusion, n (%) | 2 (1) | 3 (4) | 0.014 | 1 (1) | 3 (4) | 0.31 |
| Underwent inner suture, n (%) | 134 (64) | 51 (63) | 0.50 | 41 (55) | 50 (67) | 0.091 |
| Urinary tract entry, n (%) | 111 (53) | 39 (48) | 0.28 | 31 (41) | 38 (51) | 0.16 |
| Positive surgical margin, n (%) | 7 (3) | 6 (7) | 0.12 | 2 (3) | 6 (8) | 0.14 |
| Hospital stay, days (%) | 5 (4–6) | 6 (5–7) | 0.027 | 5 (5–6) | 6 (5–7) | 0.13 |
| Overall (Clavien-Dindo grade ≥ II) | 7 (3) | 12 (15) | < 0.001 | 1 (3) | 12 (16) | 0.001 |
| High-grade (Clavien-Dindo grade ≥ III) | 4 (2) | 3 (4) | 0.3 | 1 (1) | 3 (4) | 0.31 |
| Bleeding related | 4 (2) | 7 (9) | 0.013 | 1 (1) | 7 (9) | 0.032 |
| Urine leakage | 2 (1) | 0 (0) | 0.52 | 0 (0) | 0 (0) | 1 |
| Mortality | 0 (0) | 0 (0) | 1.0 | 0 (0) | 0 (0) | 1.0 |
| Median, % (IQR) | 92 (85–100) | 88 (81–95) | 0.005 | 93 (87–100) | 89 (81–95) | 0.003 |
| ≥ 90%, n (%) | 129 (61) | 37 (46) | 0.011 | 50 (67) | 36 (48) | 0.016 |
| ≥ 80%, n (%) | 185 (88) | 68 (84) | 0.23 | 66 (88) | 63 (84) | 0.16 |
| ≥ 70%, n (%) | 206 (98) | 77 (95) | 0.15 | 74 (99) | 71 (95) | 0.18 |
| Median 6-month decrease of eGFR, mL/min/1.73 m2 (IQR) | 5 (0–10) | 7 (4–12) | 0.001 | 5 (0–8) | 7 (4–12) | 0.002 |
| Upstaging of chronic kidney disease, n (%) | 50 (24) | 22 (27) | 0.33 | 17 (23) | 20 (27) | 0.35 |
| Trifecta achievement rate, n (%) | 165 (79) | 54 (67) | 0.027 | 63 (84) | 48 (64) | 0.004 |
ainterquartile range; bestimated glomerular filtration rate; ccortical-renorrhaphy-omitting robot-assisted partial nephrectomy; dcortical-renorrhaphy-omitting laparoscopic partial nephrectomy.